Sugi Predict

Sugi Predict / Compounds / SCHEMBL9963887

SCHEMBL9963887

SCHEMBL9963887

CC(C)(C)OC(=O)N1C(=O)C(O)C[C@H]1Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KLK7 P49862 7/20 0.45
▸ KLK5 Q9Y337 6/20 0.42
▸ PRSS1 P07477 3/20 0.41
▸ PRSS2 P07478 3/20 0.41
▸ PRSS3 P35030 3/20 0.41
▸ USP30 Q70CQ3 2/20 0.40
▸ NR1H2 P55055 5/20 0.39
▸ NR1H3 Q13133 4/20 0.39
▸ PLA2G10 O15496 1/20 0.39
▸ PLA2G5 P39877 1/20 0.39
▸ DPP4 P27487 1/20 0.38
▸ STS P08842 1/20 0.38
▸ CETP P11597 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ ABHD6 Q9BV23 1/20 0.38
▸ DAGLA Q9Y4D2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19605628 1.00 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL19605627 1.00 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL18724921 1.00 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL18874807 0.89 NR1H2 (0.41) KLK7KLK5USP30NR1H2NR1H3
SCHEMBL598389 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL598255 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL3424651 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL1908567 0.88 KLK7 (0.45) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL13717231 0.87 KLK7 (0.47) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL12519985 0.87 KLK7 (0.47) KLK7KLK5PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174219-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-11-16 — — US disclosed
US-20210155576-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-05-27 — — US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 — — US disclosed
US-10829438-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-11-10 — — US disclosed
US-10759813-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-09-01 — — US disclosed
US-20200031847-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-01-30 — — US disclosed
US-10336773-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-07-02 — — US disclosed
US-10315984-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-06-11 — — US disclosed
US-20180194776-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-07-12 — — US disclosed
US-20180194718-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-07-12 — — US disclosed
US-9045443-B2 Nitric oxide donor neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-06-02 — — US disclosed
US-8901169-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-12-02 — — US disclosed
US-8901169-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-12-02 — — US disclosed
WO-2014138053-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-09-12 — — WO disclosed
US-20140256702-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-09-11 — — US disclosed
US-20140046053-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-02-13 — — US disclosed
US-20140046053-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-02-13 — — US disclosed
US-8586536-B2 Neprilysin inhibitors THERAVANCE, INC. (US) 2013-11-19 — — US disclosed
US-20120157383-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 — — US disclosed
WO-2012082853-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759813-B2 Neprilysin inhibitors MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885
US-20140256702-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 225/4885KLK5 64/4885PRSS1 36/4885
US-11174219-B2 Neprilysin inhibitors MME, REN, ACE KLK7 262/4885KLK5 245/4885PRSS1 94/4885
US-10829438-B2 Neprilysin inhibitors MME, REN, ACE KLK7 262/4885KLK5 245/4885PRSS1 94/4885
US-20210155576-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 262/4885KLK5 245/4885PRSS1 94/4885
US-10315984-B2 Neprilysin inhibitors MME, REN, ACE KLK7 262/4885KLK5 245/4885PRSS1 94/4885
US-10336773-B2 Neprilysin inhibitors MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885
US-20210079017-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885
US-20180194776-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885
US-20200031847-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885
US-20140046053-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885
US-20180194718-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 225/4885KLK5 64/4885PRSS1 36/4885
US-20120157383-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 302/4885KLK5 152/4885PRSS1 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.